Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome

Naranie Shanmuganathan, Devendra Keshaorao Hiwase, David Morrall Ross

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Over the past two decades, tyrosine kinase inhibitors have become the foundation of chronic myeloid leukemia (CML) treatment. The choice between imatinib and newer tyrosine kinase inhibitors (TKIs) needs to be balanced against the known toxicity and efficacy data for each drug, the therapeutic goal being to maximize molecular response assessed by BCR-ABL RQ-PCR assay. There is accumulating evidence that the early achievement of molecular targets is a strong predictor of superior long-term outcomes. Early response assessment provides the opportunity to intervene early with the aim of ensuring an optimal response. Failure to achieve milestones or loss of response can have diverse causes. We describe how clinical and laboratory monitoring can be used to ensure that each patient is achieving an optimal response and, in patients who do not reach optimal response milestones, how the monitoring results can be used to detect resistance and understand its origins.

LanguageEnglish
Pages2799-2810
Number of pages12
JournalLeukemia and Lymphoma
Volume58
Issue number12
DOIs
Publication statusPublished - 2 Dec 2017

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia
  • minimal residual disease
  • resistance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Shanmuganathan, Naranie ; Hiwase, Devendra Keshaorao ; Ross, David Morrall. / Treatment of chronic myeloid leukemia : assessing risk, monitoring response, and optimizing outcome. In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 12. pp. 2799-2810.
@article{fb67f27333204446b6c2d2ca852a8892,
title = "Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome",
abstract = "Over the past two decades, tyrosine kinase inhibitors have become the foundation of chronic myeloid leukemia (CML) treatment. The choice between imatinib and newer tyrosine kinase inhibitors (TKIs) needs to be balanced against the known toxicity and efficacy data for each drug, the therapeutic goal being to maximize molecular response assessed by BCR-ABL RQ-PCR assay. There is accumulating evidence that the early achievement of molecular targets is a strong predictor of superior long-term outcomes. Early response assessment provides the opportunity to intervene early with the aim of ensuring an optimal response. Failure to achieve milestones or loss of response can have diverse causes. We describe how clinical and laboratory monitoring can be used to ensure that each patient is achieving an optimal response and, in patients who do not reach optimal response milestones, how the monitoring results can be used to detect resistance and understand its origins.",
keywords = "BCR-ABL, Chronic myeloid leukemia, minimal residual disease, resistance",
author = "Naranie Shanmuganathan and Hiwase, {Devendra Keshaorao} and Ross, {David Morrall}",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/10428194.2017.1312377",
language = "English",
volume = "58",
pages = "2799--2810",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

Treatment of chronic myeloid leukemia : assessing risk, monitoring response, and optimizing outcome. / Shanmuganathan, Naranie; Hiwase, Devendra Keshaorao; Ross, David Morrall.

In: Leukemia and Lymphoma, Vol. 58, No. 12, 02.12.2017, p. 2799-2810.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of chronic myeloid leukemia

T2 - Leukemia and Lymphoma

AU - Shanmuganathan, Naranie

AU - Hiwase, Devendra Keshaorao

AU - Ross, David Morrall

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Over the past two decades, tyrosine kinase inhibitors have become the foundation of chronic myeloid leukemia (CML) treatment. The choice between imatinib and newer tyrosine kinase inhibitors (TKIs) needs to be balanced against the known toxicity and efficacy data for each drug, the therapeutic goal being to maximize molecular response assessed by BCR-ABL RQ-PCR assay. There is accumulating evidence that the early achievement of molecular targets is a strong predictor of superior long-term outcomes. Early response assessment provides the opportunity to intervene early with the aim of ensuring an optimal response. Failure to achieve milestones or loss of response can have diverse causes. We describe how clinical and laboratory monitoring can be used to ensure that each patient is achieving an optimal response and, in patients who do not reach optimal response milestones, how the monitoring results can be used to detect resistance and understand its origins.

AB - Over the past two decades, tyrosine kinase inhibitors have become the foundation of chronic myeloid leukemia (CML) treatment. The choice between imatinib and newer tyrosine kinase inhibitors (TKIs) needs to be balanced against the known toxicity and efficacy data for each drug, the therapeutic goal being to maximize molecular response assessed by BCR-ABL RQ-PCR assay. There is accumulating evidence that the early achievement of molecular targets is a strong predictor of superior long-term outcomes. Early response assessment provides the opportunity to intervene early with the aim of ensuring an optimal response. Failure to achieve milestones or loss of response can have diverse causes. We describe how clinical and laboratory monitoring can be used to ensure that each patient is achieving an optimal response and, in patients who do not reach optimal response milestones, how the monitoring results can be used to detect resistance and understand its origins.

KW - BCR-ABL

KW - Chronic myeloid leukemia

KW - minimal residual disease

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85019100969&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1312377

DO - 10.1080/10428194.2017.1312377

M3 - Review article

VL - 58

SP - 2799

EP - 2810

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -